Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2018 07:30 ET | Source: Theratechnologies

Trogarzo(MD) obtient un code de facturation « J » spécifique du Centre for Medicare and Medicaid Services

MONTRÉAL, 08 nov. 2018 (GLOBE NEWSWIRE) -- Theratechnologies inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer qu’un code de facturation « J » spécifique a été assigné à TrogarzoMD...
November 08, 2018 07:30 ET | Source: Theratechnologies

Specific Billing J-Code Issued for Trogarzo® by Center for Medicare and Medicaid Services

MONTREAL, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo® (ibalizumab-uiyk) injection has been assigned a specific...
November 05, 2018 07:30 ET | Source: Theratechnologies

La FDA approuve la nouvelle formulation d’EGRIFTA(MD) en fiole unique

MONTRÉAL, 05 nov. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que la Food and Drug Administration aux États-Unis a approuvé la nouvelle...
November 05, 2018 07:30 ET | Source: Theratechnologies

FDA Approves Novel Single-Vial Formulation of EGRIFTA®

MONTREAL, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Food and Drug Administration in the United States has approved the...
October 31, 2018 10:45 ET | Source: Theratechnologies

Analyse des données de phase III de Trogarzo® présentée lors d’une présentation orale de dernière heure à HIV drug therapy Glasgow 2018

MONTREAL, 31 oct. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) annonce qu’une analyse additionnelle des données de l’étude clinique de phase III de TrogarzoMD...
October 31, 2018 10:45 ET | Source: Theratechnologies

Trogarzo® Phase III Data Analysis featured During Late-Breaking Oral Presentation at HIV Drug Therapy Glasgow 2018

MONTRÉAL, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced that additional analysis of phase III clinical trial data of Trogarzo®...
October 30, 2018 07:30 ET | Source: Theratechnologies

Analyse des données de la phase III de Trogarzo(MD) présentée à HIV Drug Therapy Glasgow 2018: les patients n’ayant pas atteint le principal critère d’évaluation au jour 7 ont obtenu des bénéfices cliniques en cours d’étude

MONTRÉAL, 30 oct. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) a annoncé aujourd’hui que des données issues de l’étude clinique de phase III de TrogarzoMD...
October 30, 2018 07:30 ET | Source: Theratechnologies

Trogarzo® Phase III Data Analysis Presented at HIV Drug Therapy Glasgow 2018: Patients not achieving primary endpoint at day 7 experienced clinical benefit by end of study

MONTREAL, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that data from the phase III clinical trial of Trogarzo® (ibalizumab-uiyk) injection...
October 29, 2018 07:30 ET | Source: Theratechnologies

Le United States Department of Health and Human Services publie des directives de traitement du VIH incluant Trogarzo(MD)

MONTRÉAL, 29 oct. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que TrogarzoMD (ibalizumab-uiyk) injection fait maintenant partie des...
October 29, 2018 07:30 ET | Source: Theratechnologies

United States Department of Health and Human Services Publishes New HIV Treatment Guidelines Including Trogarzo®

MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo® (ibalizumab-uiyk) injection is now included in the most recent...